GlassScriptPhysician profile
Hany Ahmed
NPI 1528038916
$1,435.45
in general payments reported to CMS, 2019-2025
26 companies · $99.50 in 2025
The $99.50 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $114 · 2020: $118 · 2021: $204 · 2022: $397 · 2023: $420 · 2024: $82.17 · 2025: $99.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $508 · Education: $94.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $508.05 |
| Education | $94.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $213.50 | 2020-2022 | |
| Astellas Pharma US INC | $136.35 | 2023 | Myrbetriq, Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $120.65 | 2019-2023 | |
| Medtronic, INC. | $108.60 | 2022 | |
| Shield Therapeutics INC | $96.41 | 2023-2024 | Accrufer |
| Baxter Healthcare | $93.24 | 2022-2023 | Tisseel |
| Hologic Sales and Service, LLC | $86.74 | 2019-2023 | Aptima |
| Merck Sharp & Dohme LLC | $79.77 | 2019-2024 | Gardasil, Gardasil 9 |
| Myovant Sciences INC. | $79.52 | 2021-2022 | |
| Caldera Medical, INC | $67.56 | 2023 | Desara |
| Mission Pharmacal Company | $44.60 | 2020-2023 | Citranatal |
| Pacira Pharmaceuticals Incorporated | $41.25 | 2022-2023 | Exparel, Iovera |
| Organon LLC | $32.39 | 2022-2025 | Jada System |
| Smith+Nephew, INC. | $24.65 | 2025 | Allevyn Heel 10.5cm X 13.5cm Ctn 5 |
| Coopersurgical, INC. | $24.58 | 2020-2021 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $23.08 | 2024 | Freestyle Libre 3 |
| Pfizer INC. | $22.57 | 2025 | |
| Sumitomo Pharma America, INC. | $21.78 | 2025 | Myfembree |
| Mayne Pharma Commercial LLC | $19.10 | 2021 | |
| Scynexis, INC. | $18.68 | 2022 | |
| Alafair Biosciences, INC. | $18.55 | 2025 | Versawrap |
| Acessa Health INC. | $18.23 | 2019 | |
| Millicent US INC | $17.07 | 2023 | Femring, Intrarosa |
| Agile Therapeutics, INC. | $14.78 | 2022 | |
| Meditrina | $11.80 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hany Ahmed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.